

Certificate of Analysis

PKC beta I, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-503, 14-503-K, 14-503M

Parent Lot # D8HN062U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged, recombinant amino acids 2–end of human PKC beta I expressed in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Purity 91% by SDS-PAGE and Coomassie blue staining. MW = 78kDa.

Specific Activity (Parent lot# D8HN062U): 2552U/mg, where one unit of PKC beta I, active activity is defined as 1nmol phosphate incorporated into 0.1mg/ml histone H1 (in the presence of lipid activator and 0.1mM CaCl₂) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.194mg/ml of enzyme in 20mM Tris/HCl pH7.5, 0.02% Triton X-100, 1mM DTT, 1mM PMSF, 10mM benzamidine, 5% glycerol, 1mM EDTA, 1mM EGTA. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 0.64–4.85ng of this lot of enzyme phosphorylated 0.1mg/ml histone H1 in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as PKC beta I with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **10 x Reaction Buffer:** 200mM HEPES/NaOH pH7.4.
2. **CaCl₂:** Make up a 1mM stock in dH₂O. Add 2.5µl of stock per assay point.
3. **Histone H1:** Use at a final assay concentration of 0.1mg/ml. Make up a 1mg/ml stock in 20mM MOPS pH7.0. Add 2.5µl of stock per assay point.
4. **10 x Lipid Activator:** 0.3% Triton X-100, 1mg/ml phosphatidylserine, 0.1mg/ml diacylglycerol). Use 2.5µl of stock per assay point.
5. **PKC beta I, active:** Dilute with 20mM HEPES/NaOH pH7.4, 0.03% Triton X-100. Use 0.64–4.85ng per assay point.
6. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 2.5µl of 10 x reaction buffer per assay.
2. Add 2.5µl of **histone H1**.
3. Add 2.5µl of PKC lipid activator.
4. Add 2.5µl of 1mM CaCl₂.
5. Add **2.5 µl (0.64–4.85ng) PKC beta I, active**.
6. Add 2.5µl with dH₂O.
7. Add 10µl of diluted [γ-³³P] ATP mixture.
8. Incubate for 10 minutes at 30°C.
9. Stop the reaction by adding 5µl of 3% phosphoric acid.
10. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
11. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
12. Wash the filtermat once for 2 minutes with methanol.
13. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
14. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

PKC beta I Sequence Information

<u>Protein</u>	Human PKC beta I
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	A2 of the recombinant protein is equivalent to A10 of human PKC beta I
<u>Accession number</u>	GenBank X06318

Recombinant PKC beta I amino acid sequence:

```

1  MHHHHHHEFA  DPAAGPPPSE  GEESTVRFAR  KGALRQKNVH  EVKNHKFTAR  FFKQPTFCSH
61  CTDFIWGFGK  QGFQCQVCCF  VVHKRCHEFV  TFSCPGADKG  PASDDPRSKH  KFKIHTYSSP
121  TFCDHCGSSL  YGLIHQGMKC  DTCMMNVHKR  CVMNVPSLCG  TDHTERRGRI  YIQAHIDRDV
181  LIVLVRDAKN  LVPMDPNGLS  DPYVKLKLIP  DPKSESKQKT  KTIKCSLNPE  WNETFRFQLK
241  ESDKDRRLSV  EIWDWDLTSR  NDFMGSLSF  ISELQKASVD  GWFKLLSQEE  GEYFNVPVPP
301  EGSEANEELR  QKFERAKISQ  GTKVPEEKTT  NTVSKFDNNG  NRDRMKLTDF  NFLMVLGKGS
361  FGKVMLSERK  GTDELYAVKI  LKKDVVIQDD  DVECTMVEKR  VLALPGKPPF  LTQLHSCFQT
421  MDRLYFVMEY  VNGGDLMYHI  QQVGRFKEPH  AVFYAAEIAI  GLFFLQSKGI  IYRDLKLDNV
481  MLDSEGHIKI  ADFGMCKENI  WDGVTTKTFC  GTPDYIAPEI  IAYQPYGKSV  DWWAFGVLLY
541  EMLAGQAPFE  GEDEDELFS  IMEHNVAYPE  SMSKEAVAIC  KGLMTKHPGK  RLGCPEGER
601  DIKEHAFFRY  IDWEKLERKE  IQPPYKPKAR  DKRDTSNFDK  EFTRQPVVELT  PTDKLFIMNL
661  DQNEFAGFSY  TNPEFVINV

```

Recombinant PKC beta I nucleotide sequence:

```

1  atgcatcatc  accatcacca  tgaattcgct  gacccggtcg  cggggcgccg  gccgagcgag
61  gccgaggaga  gcaccgtgcg  cttcgcccgc  aaaggcgccc  tccggcagaa  gaacgtgcat
121  gaggtcaaga  accacaaatt  caccgcccgc  ttcttcaagc  agcccacctt  ctgcagccac
181  tgcaccgact  tcatctgggg  cttcgggaag  cagggattcc  agtgccaagt  ttgctgcttt
241  gtggtgcaca  agcggtgcca  tgaatttgct  acattctcct  gccctggcgc  tgacaagggg
301  ccagcctccg  atgacccccg  cagcaaacac  aagtttaaga  tccacacgta  ctccagcccc
361  acgtttttgt  accactgtgg  gtcactgctg  tatggactca  tccaccaggg  gatgaaatgt
421  gacacctgca  tgatgaatgt  gcacaagcgc  tgcgtgatga  atgttcccag  cctgtgtggc
481  acggaccaca  cggagcgccg  cggccgcctc  tacatccagg  cccacatcga  cagggacgtc
541  ctcatgtgct  tcgtaagaga  tgctaaaaac  cttgtacctc  tggaccccaa  tggcctgtca
601  gatccctacg  taaaactgaa  actgattccc  gatcccaaaa  gtgagagcaa  acagaagacc
661  aaaaccatca  aatgtccctc  caaccctgag  tggaatgaga  catttagatt  tcagctgaaa
721  gaatcggaag  aagacagaag  actgtcagta  gagatttggg  attgggaatt  gaccagcagg
781  aatgacttca  tgggatcttt  gtcctttggg  atttctgaac  ttcagaaagc  cagtgttgat
841  ggctggttta  agttactgag  ccaggaggaa  ggcgagtact  tcaatgtgcc  tgtgccacca
901  gaaggaagtg  agccaatga  agaactcgcg  cagaaatttg  agagggccaa  gatcagtcag
961  ggaaccaagg  tcccggaaga  aaagacgacc  aacactgtct  ccaaatttga  caacaatggc
1021  aacagagacc  ggatgaaact  gaccgatttt  aacttcctaa  tgggtgctgg  gaaaggcagc
1081  tttggcaagg  tcatgctttc  agaacgaaaa  ggcacagatg  agctctatgc  tgtgaagatc
1141  ctgaagaagg  acgttgatga  ccaagatgat  gacgtggagt  gcaactatgg  ggagaagcgg
1201  gtgttgcccc  tgcctgggaa  gccgcccttc  ctgaccagc  tccactcctg  cttccagacc
1261  atggaccgcc  tgtactttgt  gatggagtac  gtgaatgggg  gcgacctcat  gtatcacatc
1321  cagcaagtgc  gccggttcaa  ggagccccat  gctgtatttt  acgctgcaga  aattgccatc
1381  ggtctgttct  tcttacagag  taagggcata  atttaccgtg  acctaaaact  tgacaacgtg
1441  atgctcgatt  ctgaggggca  catcaagatt  gccgattttg  gcatgtgtaa  ggaaaacatc
1501  tgggatgggg  tgacaaccaa  gacattctgt  ggcactccag  actacatcgc  ccccagata
1561  attgcttatc  agccctatgg  gaagtccgtg  gattgggtgg  catttgaggt  cctgctgtat
1621  gaaatgttgg  ctgggcaggc  accctttgaa  ggggaggatg  aagatgaact  cttccaatcc
1681  atcatggaac  acaacgtagc  ctatcccaag  tctatgtcca  aggaagctgt  ggccatctgc
1741  aaagggtgta  tgaccaaaca  ccaggcaaaa  cgtctgggtt  gtggacctga  aggccaacgt

```

Certificate of Analysis

```
1801 gatatcaaag agcatgcatt tttccggtat attgattggg agaaacttga acgcaaagag
1861 atccagcccc cttataagcc aaaagctaga gacaagagag acacctccaa cttcgacaaa
1921 gagttcacca gacagcctgt ggaactgacc cccactgata aactcttcat catgaacttg
1981 gaccaaaatg aatttgctgg cttctcttat actaaccag agtttgtcat taatgtgtag
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services.